clinical trial · NCT03082183
A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the Blood
Boehringer Ingelheim·phase1·completed·n = 16
HealthyRifampicinBI 425809
brief summary
The primary objective of this trial is to investigate the relative bioavailability of a single dose of BI 425809 when given alone (Reference, B) compared with co-administration (Test, A) on the 7th day of a 10-day treatment with rifampicin following oral administration in healthy male volunteers.
started
Mar 28, 2017
primary completion
Jun 20, 2017
completion
Jun 20, 2017
last updated
Mar 30, 2026
official title
Effects of Rifampicin on the Pharmacokinetics of BI 425809 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol